肺动脉高压阈值与死亡率增加相关
基于澳大利亚国家超声心动图数据库313,492例队列,分析157,842例受试者估算右心室收缩压(eRVSP)分布及长期生存。中位随访4.2年,严重肺动脉高压(eRVSP≥60 mm Hg)校正风险比9.73(95%CI 8.60–11.0,p<0.001)。eRVSP约30.0 mm Hg处呈现明确且一致的死亡率增加阈值。
要点
- eRVSP约30 mm Hg即与死亡率增加相关,低于现行诊断阈值。
- 严重肺动脉高压(eRVSP≥60 mm Hg)校正风险比9.73(95%CI 8.60–11.0)。
- 轻中度eRVSP升高亦与长期死亡风险增加独立相关。
核心结论
- 临床公认的肺动脉高压水平预后影响得到证实,且识别出更低的死亡率增加阈值(eRVSP>30.0 mm Hg)。
研究设计与样本
- 基于澳大利亚国家超声心动图数据库的纵向队列研究,纳入157,842名男女,中位随访4.2年(四分位距2.2–7.5年)。
主要发现
- 17,955例(11.4%)、7,016例(4.4%)、4,515例(2.9%)受试者eRVSP分别提示轻度(40–49 mm Hg)、中度(50–59 mm Hg)、重度(≥60 mm Hg)肺动脉高压(假设右房压5 mm Hg)。
- 重度肺动脉高压校正风险比9.73(95%CI 8.60–11.0,p<0.001)。
- 校正年龄、性别及左心疾病证据后,eRVSP第三五分位(28.05–32.0 mm Hg)风险比1.410(95%CI 1.310–1.517),第四五分位(32.05–38.83 mm Hg)风险比1.979(95%CI 1.853–2.114),均显著高于最低五分位(p<0.001)。
- eRVSP约30.0 mm Hg处呈现明确且一致的死亡率增加阈值(包括1年和5年 actuarial 死亡率)。
临床怎么用
- 超声心动图评估eRVSP>30.0 mm Hg时需警惕死亡风险增加,即使未达传统肺动脉高压诊断阈值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is increasing evidence that current thresholds for diagnosing pulmonary hypertension (PHT) underestimate the prognostic impact of PHT. OBJECTIVES: The aim of this study was to determine the prognostic impact of increasing pulmonary pressures within the National Echocardiography Database of Australia cohort (n = 313,492). METHODS: The distribution of estimated right ventricular systolic pressure (eRVSP) was examined in 157,842 men and women. All had data linkage to long-term survival during median follow-up of 4.2 years (interquartile range: 2.2 to 7.5 years). RESULTS: The cohort comprised 74,405 men and 83,437 women 65.6 ± 17.7 years of age. Overall, 17,955 (11.4%), 7,016 (4.4%), and 4,515 (2.9%) subjects had eRVSP levels indicative of mild (40 to 49 mm Hg), moderate (50 to 59 mm Hg), or severe (≥60 mm Hg) PHT, respectively, assuming a right atrial pressure of 5 mm Hg. These subjects were more likely to die during long-term follow up (for severe PHT, adjusted hazard ratio: 9.73; 95% confidence interval: 8.60 to 11.0; p < 0.001). After adjustment for age, sex, and evidence of left heart disease, those subjects with eRVSP levels within the third (28.05 to 32.0 mm Hg; hazard ratio: 1.410; 95% confidence interval: 1.310 to 1.517) and fourth (32.05 to 38.83 mm Hg; hazard ratio: 1.979; 95% confidence interval: 1.853 to 2.114) quintiles had significantly higher mortality (p < 0.001) than those in the lowest quintile. Accordingly, a clear and consistent threshold of increased mortality (including 1- and 5-year actuarial mortality) around an eRVSP of 30.0 mm Hg was evident. CONCLUSIONS: In this large and unique cohort, the prognostic impact of clinically accepted levels of PHT was confirmed. Moreover, a distinctly lower threshold for increased risk for mortality (eRVSP >30.0 mm Hg) indicative of PHT was identified. (A Longitudinal Cohort Study of Echocardiograms From Public and Private Echocardiography Laboratories From Around Australia, Linked With the National Deaths Index; ACTRN12617001387314).
引用
- Strange G, Stewart S, Celermajer DS, et al. Threshold of Pulmonary Hypertension Associated With Increased Mortality. J Am Coll Cardiol. 2019. PMID: 31146810. doi:10.1016/j.jacc.2019.03.482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。